# Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria

> **NCT04897919** · PHASE4 · COMPLETED · sponsor: **Bandim Health Project** · enrollment: 474 (actual)

## Conditions studied

- Malaria
- Effectiveness

## Interventions

- **DRUG:** Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet
- **DRUG:** Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT04897919
- **Lead sponsor:** Bandim Health Project
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-01
- **Primary completion:** 2017-10-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 474 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897919, "Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04897919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*